首页 > 市场调查报告书 > 製药

癌症

市场调查报告书

商品编码

1736672

2026 年至 2032 年肝癌治疗市场（按流程、类型、最终用户和地区划分）

Liver Cancer Treatment Market by Process (Targeted Therapy, Chemotherapy), Type (Hepatocellular Carcinoma, Cholangio Carcinoma), End-User (Hospitals, Clinics), & Region for 2026-2032

出版日期: 2025年05月06日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格

简介目录

肝癌治疗市场评估-2026-2032

人们对早期诊断的认识不断提高，加上成像技术的进步，推动了肝癌治疗市场规模的成长。根据 Verified Market Research 分析师预测，肝癌治疗市场规模预计在 2024 年将达到约 354 万美元，到 2032 年将达到 888 万美元。

肝癌治疗市场的快速扩张主要归因于旨在改善治疗方案和提高患者预后的研发活动投资的增加，预计从 2026 年到 2032 年，复合年增长率将达到 13.45%。

肝癌治疗市场：定义/概述

肝癌治疗是指一系列旨在控制肝癌的医疗干预措施，包括手术、化疗、标靶治疗和免疫疗法等多种治疗方法。早期发现和个人化治疗方案的重要性已被强调，以改善患者的预后和存活率。治疗方法的选择是基于癌症的分期、患者的一般状况和具体的肿瘤特征，以确保个人化的治疗方案。

对新型治疗药物研发和技术进步的日益重视被认为是肝癌治疗市场的主要成长要素。此外，由于肝炎感染和饮酒等因素导致的肝癌发生率上升也被认为是推动市场扩张的关键因素。随着人们对肝癌及其治疗方法的认识不断提高，研发投资也成为优先事项，这进一步推动了市场的成长。

加大研发投入将对肝癌治疗市场产生什么影响？

肝癌治疗市场不断增加的研发投入已产生显着影响。这些投入主要用于研发和临床试验新型治疗药物，可望提升疗效和患者预后。标靶治疗和免疫疗法也因此取得了突破，促进了整体市场的成长。

根据美国国家癌症研究所 (NCI) 的数据，美国癌症相关总支出预计将从 2015 年的 1,830 亿美元增加到 2030 年的 2,460 亿美元，其中很大一部分将用于研发工作。

此外，製药公司与研究机构之间的合作正在加速，以加快开发进程，预计将为患者带来更广泛的治疗选择。这种对技术创新的关注被认为对于满足肝癌患者尚未满足的医疗需求至关重要，也是市场扩张的驱动力。

日益增加的监管挑战如何影响肝癌治疗市场的成长？

日益严峻的监管挑战正显着影响肝癌治疗市场的成长。遵守监管机构严格的核准流程可能会延迟新治疗方法的上市。此外，由于需要进行大量的临床试验并遵守安全标准，这需要耗费大量的时间和财力，因此这些挑战更加严峻。

因此，企业被迫加大对监管策略和上市计画的投资，以有效规避这些障碍。整个行业都感受到了这种影响，因为这些监管障碍可能会扼杀创新，并延缓可能挽救生命的疗法的商业化。

Increasing awareness regarding early diagnosis and advancements in imaging technologies have been driving the growth of the liver cancer treatment market size. According to the analyst from Verified Market Research, the Liver Cancer Treatment Market is estimated to reach a valuation of USD 8.88 Million By 2032 over the forecast subjugating around USD 3.54 Million valued in 2024.

The rapid expansion of the liver cancer treatment market is primarily driven by increasing investments in research and development activities aimed at improving therapeutic options and enhancing patient outcomes. It enables the market to grow at a CAGR of 13.45% from 2026 to 2032.

Liver Cancer Treatment Market: Definition/ Overview

Liver cancer treatment is defined as a range of medical interventions aimed at managing liver cancer, which includes various therapies such as surgery, chemotherapy, targeted therapy, and immunotherapy. The significance of early detection and tailored treatment plans has been emphasized in improving patient outcomes and survival rates. Treatments are utilized based on the stage of cancer, the overall health of the patient, and specific tumor characteristics, ensuring a personalized approach to care.

Increasing focus on the development of novel therapeutic agents and advancements in technology are being recognized as key growth factors in the liver cancer treatment market. The rising prevalence of liver cancer, driven by factors such as hepatitis infections and alcohol consumption, has also been acknowledged as a crucial element contributing to market expansion. As awareness regarding liver cancer and its treatment options continues to grow, investments in research and development are being prioritized, further supporting market progression.

What Impact is Being Observed from the Rising Investments in Research and Development on the Liver Cancer Treatment Market?

A significant impact is being observed from the rising investments in research and development on the liver cancer treatment market. These investments are being directed toward the discovery and clinical testing of novel therapeutic agents, which are expected to enhance treatment efficacy and patient outcomes. As a result, breakthroughs in targeted therapies and immunotherapies are being achieved, contributing to the overall growth of the market.

According to the National Cancer Institute (NCI), the total national cancer-related expenditure in the United States is projected to increase from USD 183 Billion in 2015 to USD 246 Billion in 2030, a substantial portion of which is dedicated to research and development efforts.

Furthermore, collaborations between pharmaceutical companies and research institutions are being established to accelerate the development process, which is anticipated to result in a wider range of treatment options for patients. This focus on innovation is being recognized as essential in addressing the unmet medical needs of liver cancer patients, thereby driving market expansion.

How are Increasing Regulatory Challenges Affecting the Growth of the Liver Cancer Treatment Market?

Increasing regulatory challenges are affecting the growth of the liver cancer treatment market significantly. Stringent approval processes imposed by regulatory bodies are being observed, which can lead to delays in the introduction of new therapies into the market. These challenges are compounded by the need for extensive clinical trials and compliance with safety standards, which require substantial time and financial resources.

As a result, companies are being encouraged to invest more in regulatory strategies and market access planning to navigate these obstacles effectively. The overall impact of these regulatory hurdles is being felt across the industry, as they can inhibit innovation and slow down the commercialization of potentially life-saving treatments.

Category-Wise Acumens

What Factors are Contributing to the Dominance of Targeted Therapy in the Liver Cancer Treatment Market?

According to VMR analyst, several factors are contributing to the dominance of targeted therapy in the liver cancer treatment market. The specificity of targeted therapies, which focus on particular molecular targets associated with cancer cells, is being recognized for its ability to minimize damage to healthy tissues, leading to fewer side effects compared to traditional treatments. Additionally, significant advancements in molecular diagnostics have enabled the identification of patients who are most likely to benefit from these therapies.

The increasing prevalence of liver cancer, particularly among high-risk populations, is also being acknowledged as a driving force behind the demand for targeted treatment options. Moreover, partnerships between pharmaceutical companies and biotechnology firms are being formed to accelerate the development and commercialization of innovative targeted therapies, further solidifying this segment's leading position in the market.

What are the Key Trends Driving the Rapid Growth of Hepatocellular Carcinoma Treatments?

According to VMR Analyst, key trends driving the rapid growth of hepatocellular carcinoma treatments are being observed as the focus on early detection and improved treatment methodologies continues to increase. The rising incidence of hepatocellular carcinoma, fueled by factors such as chronic hepatitis infections and non-alcoholic fatty liver disease, is being recognized as a critical factor for market expansion. Innovative treatment options, including combination therapies that utilize both targeted agents and immunotherapy, are being developed to enhance treatment efficacy.

Furthermore, growing awareness of liver cancer symptoms and risk factors among healthcare professionals and patients is being emphasized, resulting in earlier diagnoses and timely interventions. The overall impact of these trends is anticipated to lead to a substantial increase in the adoption of hepatocellular carcinoma treatments, contributing significantly to the growth of the liver cancer treatment market.

Country/Region-wise Acumens

What are the Key Factors Contributing to the Dominance of North America in the Liver Cancer Treatment Market?

According to VMR Analyst, the dominance of North America in the liver cancer treatment market is being attributed to several key factors. Advanced healthcare infrastructure and a high level of investment in research and development are being recognized as significant contributors to the region's market leadership. Additionally, the presence of major pharmaceutical companies and biotechnology firms has facilitated the rapid development and commercialization of innovative treatment options. According to the Pharmaceutical Research and Manufacturers of America (PhRMA), the U.S. biopharmaceutical industry invested an estimated USD 91 Billion in R&D in 2020.

Strong government support for cancer research, along with favorable reimbursement policies for liver cancer treatments, is also being acknowledged as a crucial factor driving market growth. Furthermore, increasing awareness of liver cancer and its treatment options among healthcare providers and patients is being emphasized, leading to higher diagnosis rates and subsequently greater demand for treatment.

How is the Rising Incidence of Liver Cancer in the Asia Pacific Region Impacting the Growth of the Market?

According to VMR Analyst, the rising incidence of liver cancer in the Asia Pacific region is impacting the growth of the liver cancer treatment market significantly. A surge in risk factors, such as chronic hepatitis B and C infections and increasing alcohol consumption, is being observed, contributing to a higher prevalence of the disease in this area. According to the World Health Organization's GLOBOCAN 2020 data, Eastern Asia accounted for about 55.8% of new liver cancer cases globally in 2020. China alone contributed to nearly half of the global liver cancer burden, with an estimated 410,038 new cases in 2020.

The demand for effective treatment options is being fueled by an increasing population and expanding healthcare access in countries such as China and India. Moreover, governmental initiatives aimed at improving cancer care and early detection programs are being implemented, which are expected to enhance treatment rates. As a result, investments in the development of innovative therapies tailored for the unique needs of this region are being prioritized, further driving the market's expansion in Asia Pacific.

Competitive Landscape

The Liver Cancer Treatment Market's competitive landscape is characterized by a varied range of companies, including technology developers, plant operators, and service providers, all striving for market share in an increasingly dynamic and growing industry.

Some of the prominent players operating in the liver cancer treatment market include:

Bayer AG

Bristol-Myers Squibb Company

Eisai Co. Ltd.

Elli Lilly and Company

Exelixis, Inc.

Merck & Co., Inc.

Novartis AG

Pfizer, Inc.

Liver Cancer Treatment Market Recent Developments

In January 2021, F. Hoffmann-La Roche Ltd. reported updated overall survival statistics from the Phase III Mbrave150 research, which evaluated the enhanced survival rate of liver cancer patients treated with Tecentriq and Avastin.

In November 2020, F. Hoffmann-La Roche Ltd. announced the European Commission's (EU) approval of Tecentriq in conjunction with Avastin for the treatment of liver cancer, intending to expand the product line and increase brand presence in European countries.

In May 2020, the FDA authorized atezolizumab in conjunction with bevacizumab for the initial treatment of liver cancer.

1 INTRODUCTION OF GLOBAL LIVER CANCER TREATMENT MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL LIVER CANCER TREATMENT MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL LIVER CANCER TREATMENT MARKET, BY PROCESS

5.1 Overview
5.2 Targeted Therapy
5.3 Chemotherapy

6 GLOBAL LIVER CANCER TREATMENT MARKET, BY TYPE

6.1 Overview
6.2 Hepatocellular Carcinoma
6.3 Cholangio Carcinoma

7 GLOBAL LIVER CANCER TREATMENT MARKET, BY END USER

7.1 Overview
7.2 Hospitals
7.3 Clinics

8 GLOBAL LIVER CANCER TREATMENT MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Rest of the World
- 8.5.1 Latin America
- 8.5.2 Middle East & Africa

9 GLOBAL LIVER CANCER TREATMENT MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Ranking
9.3 Key Development Strategies

10 COMPANY PROFILES

10.1 Merck & Co. Inc.
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 Onyx Pharmaceuticals Inc.
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 Alnylam Pharmaceuticals, Inc.
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 Bayer AG
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 Jennerex Biotherapeutics Inc.
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 Celsion Corp
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 Celsion Corp
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 ArQule Inc.
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.10 Pfizer Inc.
- 10.10.1 Overview
- 10.10.2 Financial Performance
- 10.10.3 Product Outlook
- 10.10.4 Key Developments
10.10 F. Hoffmann-La Roche AG
- 10.10.1 Overview
- 10.10.2 Financial Performance
- 10.10.3 Product Outlook
- 10.10.4 Key Developments

11 KEY DEVELOPMENTS

11.1 Product Launches/Developments
11.2 Mergers and Acquisitions
11.3 Business Expansions
11.4 Partnerships and Collaborations

12 Appendix

12.1 Related Research

02-2729-4219

+886-2-2729-4219

License/价格

2026 年至 2032 年肝癌治疗市场（按流程、类型、最终用户和地区划分）

Liver Cancer Treatment Market by Process (Targeted Therapy, Chemotherapy), Type (Hepatocellular Carcinoma, Cholangio Carcinoma), End-User (Hospitals, Clinics), & Region for 2026-2032

肝癌治疗市场评估-2026-2032

加大研发投入将对肝癌治疗市场产生什么影响？

日益增加的监管挑战如何影响肝癌治疗市场的成长？

目录

第一章 全球肝癌治疗市场介绍

第二章执行摘要

第三章：已验证的市场研究调查方法

第四章 全球肝癌治疗市场展望

第五章 全球肝癌治疗市场（依治疗过程划分）

第六章全球肝癌治疗市场（按类型）

第七章全球肝癌治疗市场（依最终用户）

第八章 全球肝癌治疗市场（按地区）

第九章全球肝癌治疗市场的竞争格局

第十章 公司简介

第十一章 重大进展

第十二章 附录

Liver Cancer Treatment Market Valuation - 2026-2032